Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases

被引：68

作者：

Pichai, Madharasi V. A. ^{[1
]}

Ferguson, Lynnette R. ^{[1
]}

机构：

[1] Univ Auckland, Discipline Nutr, Fac Med & Hlth Sci, Auckland Mail Ctr, Auckland 1142, New Zealand

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2012年 / 18卷 / 23期

关键词：

Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Tumor necrosis factor-alpha; Nanomedicine; TUMOR-NECROSIS-FACTOR; CROHNS-DISEASE; ULCERATIVE-COLITIS; MATRIX METALLOPROTEINASES; BIOLOGICAL THERAPIES; GENE-EXPRESSION; SUSCEPTIBILITY LOCI; RNA INTERFERENCE; TISSUE INHIBITOR; EPITHELIAL-CELLS;

D O I：

10.3748/wjg.v18.i23.2895

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Inflammatory bowel diseases (IBDs) such as Crohn's disease are highly debilitating. There are inconsistencies in response to and side effects in the current conventional medications, failures in adequate drug delivery, and the lack of therapeutics to offer complete remission in the presently available treatments of IBD. This suggests the need to explore beyond the horizons of conventional approaches in IBD therapeutics. This review examines the arena of the evolving IBD nanomedicine, studied so far in animal and in vitro models, before comprehensive clinical testing in humans. The investigations carried out so far in IBD models have provided substantial evidence of the nanotherapeutic approach as having the potential to overcome some of the current drawbacks to conventional IBD therapy. We analyze the pros and cons of nanotechnology in IBD therapies studied in different models, aimed at different targets and mechanisms of IBD pathogenesis, in an attempt to predict its possible impact in humans. (C) 2012 Baishideng. All rights reserved.

引用

页码：2895 / 2901

页数：7

共 77 条

[1]

The molecular classification of the clinical manifestations of Crohn's disease [J].

Ahmad, T ;

Armuzzi, A ;

Bunce, M ;

Mulcahy-Hawes, K ;

Marshall, SE ;

Orchard, TR ;

Crawshaw, J ;

Large, O ;

De Silva, A ;

Cook, JT ;

Barnardo, M ;

Cullen, S ;

Welsh, KI ;

Jewell, DP .

GASTROENTEROLOGY, 2002, 122 (04) :854-866

[2]

MACROPHAGE HETEROGENEITY IN NORMAL COLONIC MUCOSA AND IN INFLAMMATORY BOWEL-DISEASE [J].

ALLISON, MC ;

CORNWALL, S ;

POULTER, LW ;

DHILLON, AP ;

POUNDER, RE .

GUT, 1988, 29 (11) :1531-1538

[3]

Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation [J].

Aouadi, Myriam ;

Tesz, Gregory J. ;

Nicoloro, Sarah M. ;

Wang, Mengxi ;

Chouinard, My ;

Soto, Ernesto ;

Ostroff, Gary R. ;

Czech, Michael P. .

NATURE, 2009, 458 (7242) :1180-U116

[4]

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease [J].

Barrett, Jeffrey C. ;

Hansoul, Sarah ;

Nicolae, Dan L. ;

Cho, Judy H. ;

Duerr, Richard H. ;

Rioux, John D. ;

Brant, Steven R. ;

Silverberg, Mark S. ;

Taylor, Kent D. ;

Barmada, M. Michael ;

Bitton, Alain ;

Dassopoulos, Themistocles ;

Datta, Lisa Wu ;

Green, Todd ;

Griffiths, Anne M. ;

Kistner, Emily O. ;

Murtha, Michael T. ;

Regueiro, Miguel D. ;

Rotter, Jerome I. ;

Schumm, L. Philip ;

Steinhart, A. Hillary ;

Targan, Stephan R. ;

Xavier, Ramnik J. ;

Libioulle, Cecile ;

Sandor, Cynthia ;

Lathrop, Mark ;

Belaiche, Jacques ;

Dewit, Olivier ;

Gut, Ivo ;

Heath, Simon ;

Laukens, Debby ;

Mni, Myriam ;

Rutgeerts, Paul ;

Van Gossum, Andre ;

Zelenika, Diana ;

Franchimont, Denis ;

Hugot, Jean-Pierre ;

de Vos, Martine ;

Vermeire, Severine ;

Louis, Edouard ;

Cardon, Lon R. ;

Anderson, Carl A. ;

Drummond, Hazel ;

Nimmo, Elaine ;

Ahmad, Tariq ;

Prescott, Natalie J. ;

Onnie, Clive M. ;

Fisher, Sheila A. ;

Marchini, Jonathan ;

Ghori, Jilur .

NATURE GENETICS, 2008, 40 (08) :955-962

[5]

Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease [J].

Bhavsar, M. D. ;

Amiji, M. M. .

GENE THERAPY, 2008, 15 (17) :1200-1209

[6]

Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms [J].

Bruewer, M ;

Luegering, A ;

Kucharzik, T ;

Parkos, CA ;

Madara, JL ;

Hopkins, AM ;

Nusrat, A .

JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :6164-6172

[7]

Defective IL-10 production in severe phenotypes of Crohn's disease [J].

Correa, Ismael ;

Veny, Marisol ;

Esteller, Miriam ;

Pique, Josep M. ;

Yaguee, Jordi ;

Panes, Julian ;

Salas, Azucena .

JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 85 (05) :896-903

[8]

The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease [J].

Cuthbert, AP ;

Fisher, SA ;

Mirza, MM ;

King, K ;

Hampe, J ;

Croucher, PJP ;

Mascheretti, S ;

Sanderson, J ;

Forbes, A ;

Mansfield, J ;

Schreiber, S ;

Lewis, CM ;

Mathew, CG .

GASTROENTEROLOGY, 2002, 122 (04) :867-874

[9]

Anti-TNF therapy for Crohn's disease [J].

D'Haens, G .

CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (04) :289-294

[10]

Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium [J].

des Rieux, A ;

Ragnarsson, EGE ;

Gullberg, E ;

Préat, V ;

Schneider, YJ ;

Artursson, P .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 25 (4-5) :455-465

← 1 2 3 4 5 6 7 8 →